Improving hypertension quality measurement using electronic health records

Medical Care

Volumn 47, Issue 4, 2009, Pages 388-394

  Persell, Stephen D ^a,b,c,d   Kho, Abel N ^a   Thompson, Jason A ^a   Baker, David W ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^d NONE   (United States)

Author keywords

hypertension, quality measurement, quality of care, medical records systems, computerized, outcome and process assessment, healthcare

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ACCOUNTING; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DATA ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PHYSICIAN; QUALITY CONTROL; SYSTOLIC HYPERTENSION; AGED; BLOOD PRESSURE; HEALTH CARE QUALITY; MEDICAL RECORD; MIDDLE AGED; PHYSIOLOGY; STANDARD;

AGED; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE;

EID: 64249153704     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31818b070c     Document Type: Article

References (45)

1. NCQA. Measuring quality, improving health care. Available at: http://web.ncqa.org. Accessed August 31, 2007.
2. Centers for Medicare and Medicaid Services. Physician Quality Reporting Initiative. Available at: http://www.cms.hhs.gov/PQRI/01-Overview. asp. Accessed August 31, 2007.
3. Eddy DM. Performance measurement: problems and solutions. Health Aff (Millwood). 1998;17:7-25.
4. Pogach LM, Tiwari A, Maney M, et al. Should mitigating comorbidities be considered in assessing healthcare plan performance in achieving optimal glycemic control? Am J Manag Care. 2007; 13: 133-140.
5. Walter LC, Davidowitz NP, Heineken PA, et al. Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure. JAMA. 2004;291:2466-2470.
6. Hofer TP, Hayward RA, Greenfield S, et al. The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease. JAMA. 1999;281:2098-2105.
7. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716-724.
8. Werner RM, Asch DA. The unintended consequences of publicly reporting quality information. JAMA. 2005;293:1239-1244.
9. Alexander M, Tekawa I, Hunkeler E, et al. Evaluating hypertension control in a managed care setting. Arch Intern Med. 1999;159:2673-2677.
10. Rosner B, Polk BF. The implications of blood pressure variability for clinical and screening purposes. J Chronic Dis. 1979;32:451-461.
11. Rosner B, Polk BF. Predictive values of routine blood pressure measurements in screening for hypertension. Am J Epidemiol. 1983;117: 429-442.
12. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
13. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
14. Hayward RA. All-or-nothing treatment targets make bad performance measures. Am J Manag Care. 2007;13:126-128.
15. Green BB, Kaplan RC, Psaty BM. How do minor changes in the definition of blood pressure control affect the reported success of hypertension treatment? Am J Manag Care. 2003;9:219-224.
16. Broad J, Wells S, Marshall R, et al. Zero end-digit preference in recorded blood pressure and its impact on classification of patients for pharmacologic management in primary care-PREDICT-CVD-6. Br J Gen Pract. 2007;57: 897-903.
17. Niyonsenga T, Vanasse A, Courteau J, et al. Impact of terminal digit preference by family physicians and sphygmomanometer calibration errors on blood pressure value: implication for hypertension screening. J Clin Hypertens (Greenwich). 2008;10:341-347.
18. Farnett L, Mulrow CD, Linn WD, et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489-495.
19. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351: 1755-1762.
20. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884-893.
21. Protogerou AD, Safar ME, Iaria P, et al. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension. 2007;50:172-180.
22. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
23. Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care. 2004;10:163-170.
24. Kerr EA, Smith DM, Hogan MM, et al. Building a better quality measure: are some patients with 'poor quality' actually getting good care? Med Care. 2003;41:1173-1182.
25. Mehrotra A, Pearson SD, Coltin KL, et al. The response of physician groups to P4P incentives. Am J Manag Care. 2007;13:249-255.
26. Berlowitz DR, Ash AS, Hickey EC, et al. Outcomes of hypertension care. Simple measures are not that simple. Med Care. 1997;35:742-746.
27. Rodondi N, Peng T, Karter AJ, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med. 2006;144:475-484.
28. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339: 1957-1963.
29. Rose AJ, Shimada SL, Rothendler JA, et al. The accuracy of clinician perceptions of "usual" blood pressure control. J Gen Intern Med. 2008;23:180-183.
30. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23:588-594.
31. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162:413-420.
32. Hayward RA, Hofer TP, Kerr EA, et al. Quality improvement initiatives: issues in moving from diabetes guidelines to policy. Diabetes Care. 2004;27(Suppl 2):B54-B60.
33. Lee TH, Cleeman JI, Grundy SM, et al. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA. 2000;283:94-98.
34. Aron D, Rajan M, Pogach LM. Summary measures of quality of diabetes care: comparison of continuous weighted performance measurement and dichotomous thresholds. Int J Qual Health Care. 2007;19:29-36.
35. Pogach L, Engelgau M, Aron D. Measuring progress toward achieving hemoglobin Ale goals in diabetes care: pass/fail or partial credit. JAMA. 2007;297:520-523.
36. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
37. Muxfeldt ES, Bloch KV, Nogueira Ada R, et al. True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens. 2005;18(12 Pt 1):1534-1540.
38. Kerr EA, Krein SL, Vijan S, et al. Avoiding pitfalls in chronic disease quality measurement: a case for the next generation of technical quality measures. Am J Manag Care. 2001;7:1033-1043.
39. Voorham J, Denig P, Wolffenbuttel BH, et al. Cross-sectional versus sequential quality indicators of risk factor management in patients with type 2 diabetes. Med Care. 2008;46:133-141.
40. Boutitie F, Gueyffier F, Pocock S, et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med. 2002; 136: 438-448.
41. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788.
42. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849-857.
43. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290:199-206.
44. Goulet JL, Erdos J, Kancir S, et al. Measuring performance directly using the veterans health administration electronic medical record: a comparison with external peer review. Med Care. 2007;45:73-79.
45. Berwick DM, James B, Coye MJ. Connections between quality measurement and improvement. Med Care. 2003;41(Suppl):I30-I38.